HuGE Literature Finder
Records
1
-
1
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. The Lancet. Oncology 2016 Jul . Brose Marcia S, Cabanillas Maria E, Cohen Ezra E W, Wirth Lori J, Riehl Todd, Yue Huibin, Sherman Steven I, Sherman Eric |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jun 28, 2022
- Content source: